Literature DB >> 1157007

Incidence and sites of bone lesions detected by 99mTc-polyphosphate scans in patients with tumors.

R E Belliveau, R P Spencer.   

Abstract

The value of bone scanning with 99mTc-polyphosphate was assessed in 186 patients with various types of tumors. The sensitivity of this technique was greater than that of metastatic roentgenographic series and the reported results of 85-Sr-bone scans, in the detection of osseous involvement by tumors. Three cases with normal bone scans and abnormal roentgenographic studies illustrated the necessity and complementary value of comparing bone scan findings with radiographic studies. Patients with carcinoma of the breast, lung, or prostate displayed characteristic patterns of bone involvement by their tumors. The importance of clinical information, including bone symptoms, antecedent bone disease, and serum calcium and alkaline phosphatase, was stressed in the detection and interpretation of bone scan abnormalities.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157007     DOI: 10.1002/1097-0142(197508)36:2<359::aid-cncr2820360210>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  An evaluation of bone scans as screening procedures for occult metastases in primary breast cancer.

Authors:  R R Baker; E R Holmes; P O Alderson; N F Khouri; H N Wagner
Journal:  Ann Surg       Date:  1977-09       Impact factor: 12.969

2.  Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients.

Authors:  G L Smith; A P Doherty; L M Banks; J Dutton; L W Hanham; T J Christmas; R J Epstein
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Usefulness of pinhole collimator in differential diagnosis of metastatic disease and degenerative joint disease in the vertebrae; evaluation by receiver operating characteristics (ROC) analysis.

Authors:  S Kosuda; S Kawahara; A Ishibashi; K Tamura; Y Tsukatani; H Fujii; A Kubo; S Hashimoto
Journal:  Ann Nucl Med       Date:  1989-11       Impact factor: 2.668

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.